Výsledky vyhledávání - "Fadi S. Braiteh"

Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors

Autor: Shubham Pant, Erika Hamilton, Susanna V. Ulahannan, James F. Strauss, Fadi S. Braiteh, Mo Huang, Danny Chih Hsun Liaw

Publikováno v: Cancer. 129:1919-1929

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f70e0a66348bd508e6306d476d694f4d
https://doi.org/10.1002/cncr.34733

Zobrazit plný text záznamu

Real-world persistence and adherence with oral trifluridine/tipiracil or regorafenib in patients with colorectal cancer

Autor: Fadi S. Braiteh, Cynthia J. Girman, Jessica C. Young, Mark D. Danese, Debra E. Irwin, Reza Kazerooni, Tehseen Salimi, Robert Morlock, Robert S. Epstein

Publikováno v: Journal of Clinical Oncology. 40:49-49

49 Background: Trifluridine/tipiracil (FTD/TPI) and regorafenib are among the limited treatment options in later lines of therapy for patients with advanced colorectal cancer (CRC). While these treatments have demonstrated similar efficacy, differenc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::37224204279d5d8f6a4bd504b49a78bd
https://doi.org/10.1200/jco.2022.40.4_suppl.049

Zobrazit plný text záznamu

Abstract PD1-6: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer

Autor: Leisha A Emens, Fadi S Braiteh, Philippe Cassier, Jean-Pierre DeLord, Joseph Paul Eder, Xiaodong Shen, Yuanyuan Xiao, Yan Wang, Priti S Hegde, Daniel S Chen, Ian Krop

Publikováno v: Cancer Research. 75:PD1-6

Background: Metastatic triple-negative breast cancer (TNBC) is associated with a poor prognosis and has no targeted therapy options. Programmed death-ligand 1 (PD-L1) expression is more prevalent in TNBC than in other breast cancer subtypes. PD-L1 ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ce7adf009266e4cd627c58ee6a831ff6
https://doi.org/10.1158/1538-7445.sabcs14-pd1-6

Zobrazit plný text záznamu

Updated overall survival (OS) analysis of NAPOLI-1: Phase 3 study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine (gem)-based therapy

Publikováno v: Journal of Clinical Oncology. 34:4126-4126

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e2e36e2af20acdcd2d860df30316c51c
https://doi.org/10.1200/jco.2016.34.15_suppl.4126

Zobrazit plný text záznamu

Comparative effectiveness and resource utilization of nab-paclitaxel plus gemcitabine (nab-P+G) versus FOLFIRINOX (FFX) in first-line treatment of advanced pancreatic adenocarcinoma (PDAC) in a U.S. community oncology setting

Autor: Fadi S. Braiteh, Manish Patel, Monika Parisi, Quanhong Ni, Si yeon Park, Claudio Faria

Publikováno v: Journal of Clinical Oncology. 34:433-433

433 Background: Both nab-P+G and FFX demonstrated superior overall survival (OS) over gemcitabine monotherapy for the treatment of PDAC; but there is no real-world effectiveness and utilization study of nab-P+G vs. FFX. The objective of this study is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b67e745d41228048ef1cd03bfc534393
https://doi.org/10.1200/jco.2016.34.4_suppl.433

Zobrazit plný text záznamu

Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial

Publikováno v: Journal of Clinical Oncology. 31:8028-8028

8028 Background: KRAS-mutant NSCLC, usually reflecting tobacco-related carcinogenesis, represents an unmet medical need in lung cancer therapy. Trametinib plus docetaxel (doc) enhances growth inhibition and apoptosis of NSCLC cell lines in vitro with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7b4e7a877746256eeaad42dce749b286
https://doi.org/10.1200/jco.2013.31.15_suppl.8028

Zobrazit plný text záznamu

Akademický článek

Liposome‐encapsulated curcumin: In vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis.

Autor: Lan Li, Fadi S. Braiteh, Razelle Kurzrock

Publikováno v: Cancer (0008543X); Sep2005, Vol. 104 Issue 6, p1322-1331, 10p

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání